#DYAI

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone Dyadic Applied BioSolutions (NASDAQ: DYAI) and Inzymes ApS announced planned 2026 commercialization of recombinant non-animal bovine chymosin for cheese production after completing final development activities.Dyadic received a $200,000 milestone payment and remains eligible for royalties on future commercial sales; the global dairy processing enzyme market is estimated at $1.5–$2.0 billion annually.

1 week ago

#DYAI Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

www.stocktitan.net/news/DYAI/dyadic-applied...

0 0 0 0

@smcapstrategist.bsky.social

2 months ago

#DYAI Layers of Commercialization Agreements buff.ly/zQtanwA

#BiotechInnovation #ResearchAndDevelopment #LifeSciences

0 0 0 0

Small Cap Strategist

3 months ago

Leading Indicators, Monday December 1, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Mon Dec 1st - #TAOP #SGN #IWF #HUBC #DXST #VCIC #PRPH #JSPR #DYAI #CNEY #EVAC - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets Dyadic (NASDAQ:DYAI) and BRIG BIO signed a Development & Commercialization Agreement on Dec 1, 2025 to jointly develop recombinant bovine alpha-lactalbumin for infant, clinical, active, and healthy-aging nutrition markets.Under the deal, BRIG BIO will fully fund the development program and receive a global commercial license to Dyadic’s production strains in the Dapibus™ fungal expression system; Dyadic will receive milestone payments, long-term shared revenue participation, and co-marketing/sales rights. The partners target scalable, cost-effective, animal-free production to address a market projected from ~USD 760M (2025) to >USD 1.6B (2035).

3 months ago

#DYAI Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

www.stocktitan.net/news/DYAI/dyadic-and-bri...

0 0 0 0

3 months ago

#DYAI: Purchase Orders Rolling In buff.ly/kRetmOw

0 0 0 0

Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress Dyadic (NASDAQ: DYAI) reported Q3 2025 results and strategic progress on Nov 12, 2025, highlighting a commercial pivot and rebrand to Dyadic Applied BioSolutions. Key updates include a non-exclusive CRISPR/Cas9 license with ERS Genomics, first purchase orders in cell culture media and reagent segments, peer-reviewed validation of the C1 platform for SARS-CoV-2 spike production, and multiple program milestones across life sciences, nutrition, and bioindustrial markets.Financially, Dyadic held $10.4M cash and equivalents as of Sept 30, 2025, completed an equity offering that raised net proceeds of $4.9M, reported Q3 revenue of $1.165M (down from $1.958M YoY), and a net loss of $1.976M (or $(0.06) per share).

4 months ago

#DYAI Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

www.stocktitan.net/news/DYAI/dyadic-announc...

0 0 0 0

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics Dyadic Applied BioSolutions (NASDAQ:DYAI) announced a commercial CRISPR/Cas9 license from ERS Genomics on Nov 10, 2025, granting access to ERS’ global patent portfolio to support genetic engineering across Dyadic’s C1 and Dapibus bioproduction platforms. The license is intended to accelerate strain engineering, pathway optimization, and integration of CRISPR gene editing into Dyadic’s internal pipeline and partner projects across life sciences, food & nutrition, and bio-industrial sectors.ERS Genomics holds a portfolio of 100+ patents and reports 150+ licenses worldwide; financial terms of this agreement were not disclosed.

4 months ago

#DYAI Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

www.stocktitan.net/news/DYAI/dyadic-applied...

0 0 0 0

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments Dyadic Applied BioSolutions (NASDAQ: DYAI) reported commercial and product milestones in Q3 2025, including milestone payments and progress across life sciences and food & nutrition programs.Key discrete items: a $500,000 productivity milestone for recombinant human albumin with payment expected in Q4 2025, and a $250,000 milestone received from the Inzymes partnership after Q3 2025 productivity improvements. Proliant has begun sampling albumin with a commercial launch targeted in late 2025–early 2026. Dyadic also reported sampling/production starts for transferrin, research-grade DNase I meeting activity and purity benchmarks, and a signed term sheet for non-animal human alpha-lactalbumin for infant nutrition. Several enzyme candidates are advancing with scale-up on track for late 2025.

5 months ago

#DYAI Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

www.stocktitan.net/news/DYAI/dyadic-applied...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Leading Indicators, Wednesday August 20, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Wed Aug 20th - #UPLD #TACO #SAVA #OSPN #NVNO #MCRI #LNSR #KIDS #JAMF #IRBT #RELI #ZSPC #VLN #WBH #YEXT #AXGN #BXFD #CRIS #DYAI #EXFY #FCEL #GGR #UMA #TFIN #SSTK - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

7 months ago

#DYAI: One Strain To Rule Them All buff.ly/mg6iFag

0 0 0 0

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress Dyadic International (NASDAQ: DYAI) reported Q2 2025 financial results and strategic developments, marking its transformation from R&D to commercial operations. The company has rebranded as Dyadic Applied BioSolutions and completed a $5.3 million equity offering to strengthen its position.Q2 financial highlights include revenue of $967,000 (up from $386,000 YoY), with a reduced net loss of $1.794 million ($0.06 per share). Cash position stands at $7.3 million as of June 30, 2025, plus $5.3 million from the August offering.Key developments include advancing commercial launches of DNase I and recombinant albumin with Proliant, receiving $1.0 million in milestone payments, and progress in multiple protein programs across life sciences, nutrition, and bio-industrial markets. The company also secured grants from the Gates Foundation and CEPI for vaccine development.

7 months ago

#DYAI Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

www.stocktitan.net/news/DYAI/dyadic-reports...

0 0 0 0

Dyadic International Raises Capital: 6 Million Share Offering to Fuel Precision Protein Development Biotech firm secures funding for precision protein development and market expansion. Craig-Hallum leads 6.05M share offering closing Aug 1. See growth strategy.

7 months ago

#DYAI Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

www.stocktitan.net/news/DYAI/dyadic-interna...

0 0 0 0

Dyadic International Announces Strategic Stock Offering: Biotech Platform Expansion Plans Revealed Precision protein biotech firm seeks capital for product development and market expansion. Craig-Hallum leads offering of common stock. Get offering details.

7 months ago

#DYAI Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/DYAI/dyadic-interna...

0 0 0 0

Dyadic's Strategic Pivot: From Research to Revenue as New Commercial Biotech Powerhouse Dyadic transforms into Applied BioSolutions, advancing commercial protein production while securing Gates Foundation funding and enzyme development milestone. Learn more.

8 months ago

#DYAI Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

www.stocktitan.net/news/DYAI/dyadic-interna...

0 0 0 0

9 months ago

#DYAI: Fermbox Purchase Order buff.ly/wg1K18f

0 0 0 0

Dyadic Lands Major CEPI and Gates Foundation Grants as Protein Platform Nears Commercial Launch Dyadic receives $4.5M CEPI grant and $3M Gates Foundation funding while advancing protein production platform. Q3 launch planned for key products. See expansion details.

10 months ago

#DYAI Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

www.stocktitan.net/news/DYAI/dyadic-reports...

0 0 0 0

11 months ago

#DYAI: CEPI Grants Recognize C1 buff.ly/hKdW91c

0 0 0 0

Dyadic Boosts Revenue 20%, Lands Major Gates Foundation and CEPI Backing Revenue jumps to $3.5M as biotech firm advances protein platforms. Gates Foundation and CEPI grants worth $7.5M accelerate commercial pipeline. See full analysis inside.

11 months ago

#DYAI Dyadic Reports 2024 Year-End Financial Results and Business Updates

www.stocktitan.net/news/DYAI/dyadic-reports...

0 0 0 0

Breakthrough: New Dyadic Technology Slashes Vaccine Production Time from 6 Months to 35 Days Revolutionary C1 fungus technology could cut vaccine production time by 75%. CEPI backs Dyadic's innovative approach to accelerate global pandemic response capabilities.

11 months ago

#DYAI Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

www.stocktitan.net/news/DYAI/dyadic-announc...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Tue Mar 18th - #LPRO #INFN #GYRE #DYAI #ARQQ #YSG #VEL #HUYA #CNF #BKKT #PFC #QMCO #RDHL #SANA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

1 year ago

#DYAI: Looking Toward Product Revenues buff.ly/4hsd6BN

0 0 0 0

1 year ago

#DYAI Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

www.stocktitan.net/news/DYAI/dyadic-receive...

0 0 0 0

Trump Media (NASDAQ: DJT) Soaring in Pre-Market After Assassination Attempt; Bullish Sentiment on Small Caps: PRSO, VTAK, DYAI, INBS Getting your Trinity Audio player ready... July 15, 2024 – In an unprecedented surge, Trump Media & Technology Group (NASDAQ: DJT) saw its stock price skyrocket in pre-market trading today, following ...

1 year ago

Eyes On #DJT
Bullish Sentiment on Small Caps: #PRSO, #VTAK, #DYAI, #INBS
thestreetreports.com/trump-media-...

0 0 0 0

SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL Getting your Trinity Audio player ready... Investors seeking promising opportunities in the biotech and tech sectors should keep an eye on several companies showing potential for significant market tu...

1 year ago

(9) SmallCap Biotech & Tech Companies To Watch
thestreetreports.com/10-smallcap-...
#PRSO #ZVSA #DYAI #RLMD #VTAK #INBS #KAVL

0 0 0 0

Giants67

@giants1967.bsky.social

1 year ago

Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025 Getting your Trinity Audio player ready... Dyadic International (NASDAQ: DYAI), a global leader in cell culture solutions, announced a strategic partnership with Proliant Health and Biologicals (PHB),...

#DYAI Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025
thestreetreports.com/dyadic-intl-...

0 0 0 0

Spotlight June 2024: NASDAQ Stocks Under $2 Achieving Major Milestones: TELL, DYAI, PRSO, SPEC, INBS Getting your Trinity Audio player ready... In recent days, a surge of interest has spotlighted several key companies, capturing significant attention from investors. This feature delves into a detaile...

1 year ago

#DYAI #INBS #DYAI
5 NASDAQ Stocks trading Under $2
thestreetreports.com/spotlight-ju...

0 0 0 0